{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T01:40:50Z","timestamp":1792633250999,"version":"4.5.0"},"reference-count":59,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2016,6,1]],"date-time":"2016-06-01T00:00:00Z","timestamp":1464739200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,4,27]],"date-time":"2016-04-27T00:00:00Z","timestamp":1461715200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007723","name":"Takeda Pharmaceuticals U.S.A.","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007723","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Neuropsychopharmacology"],"published-print":{"date-parts":[[2016,6]]},"DOI":"10.1016\/j.euroneuro.2016.03.007","type":"journal-article","created":{"date-parts":[[2016,3,26]],"date-time":"2016-03-26T04:57:43Z","timestamp":1458968263000},"page":"979-993","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":151,"title":["A meta-analysis of randomized, placebo-controlled trials of vortioxetine for the treatment of major depressive disorder in adults"],"prefix":"10.1016","volume":"26","author":[{"given":"Michael E.","family":"Thase","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atul R.","family":"Mahableshwarkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianne","family":"Dragheim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"Loft","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduard","family":"Vieta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euroneuro.2016.03.007_bib1","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1017\/S1461145711001027","article-title":"A double-blind, randomized, placebo-controlled, active reference study of Lu AA21004 in patients with major depressive disorder","volume":"15","author":"Alvarez","year":"2012","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2016.03.007_bib2","series-title":"Work Group on Major Depressive Disorder. Practice Guideline for the Treatment of Patients with Major Depressive Disorder","author":"American Psychiatric Association (APA)","year":"2010"},{"key":"10.1016\/j.euroneuro.2016.03.007_bib3","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/S0033-3506(03)00105-7","article-title":"Meta-analysis of published studies or meta-analysis of individual data? Caesarean section in HIV-positive women as a study case","volume":"117","author":"Angelillo","year":"2003","journal-title":"Public Health"},{"key":"10.1016\/j.euroneuro.2016.03.007_bib4","first-page":"13","article-title":"A population pharmacokinetic (PK)-pharmacodynamic (PD) meta-analysis of vortioxetine in patients with major depressive disorder (MDD)","volume":"17","author":"Areberg","year":"2013","journal-title":"Int. J. Psychiatry Clin. Pract."},{"key":"10.1016\/j.euroneuro.2016.03.007_bib5","series-title":"Encyclopedia of Biostatistics","first-page":"2570","article-title":"Meta-analysis of clinical trials","author":"Armitage","year":"1998"},{"key":"10.1016\/j.euroneuro.2016.03.007_bib6","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.euroneuro.2011.11.008","article-title":"A randomised, double-blind, placebo controlled, duloxetine-referenced, fixed-dose study of three dosages of Lu AA21004 in acute treatment of major depressive disorder (MDD)","volume":"22","author":"Baldwin","year":"2012","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2016.03.007_bib7","doi-asserted-by":"crossref","first-page":"3206","DOI":"10.1021\/jm101459g","article-title":"Discovery of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): a novel multimodal compound for the treatment of major depressive disorder","volume":"54","author":"Bang-Andersen","year":"2011","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.euroneuro.2016.03.007_bib8","doi-asserted-by":"crossref","first-page":"221","DOI":"10.4236\/pp.2015.64024","article-title":"Evaluation efficacy and safety of vortioxetine 20mg\/d versus placebo for treatment major depressive disorder: a systematic review and meta-analysis of randomized controlled trials","volume":"6","author":"Behzadifar","year":"2015","journal-title":"Pharmacol. Pharm."},{"key":"10.1016\/j.euroneuro.2016.03.007_bib9","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1186\/s12888-014-0276-x","article-title":"Vortioxetine in the treatment of adult patients with major depressive disorder: a meta-analysis of randomized double-blind controlled trials","volume":"14","author":"Berhan","year":"2014","journal-title":"BMC Psychiatry"},{"key":"10.1016\/j.euroneuro.2016.03.007_bib10","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1097\/YIC.0000000000000018","article-title":"Efficacy and safety of vortioxetine (Lu AA21004), 15 and 20mg\/day: a randomized, double-blind, placebo-controlled, duloxetine-referenced study in the acute treatment of adult patients with major depressive disorder","volume":"29","author":"Boulenger","year":"2014","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2016.03.007_bib11","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.jad.2007.07.023","article-title":"Cross-national difference in the prevalence of depression caused by the diagnostic threshold","volume":"106","author":"Chang","year":"2008","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.euroneuro.2016.03.007_bib12","doi-asserted-by":"crossref","first-page":"2830","DOI":"10.1038\/npp.2012.153","article-title":"A meta-analysis of factors impacting detection of antidepressant efficacy in clinical trials: the importance of academic sites","volume":"37","author":"Dunlop","year":"2012","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.euroneuro.2016.03.007_bib13","series-title":"ECDEU Assessment Manual for Psychopharmacology","article-title":"Clinical global impressions (028-CGI)","author":"Guy","year":"1976"},{"key":"10.1016\/j.euroneuro.2016.03.007_bib14","unstructured":"H. Lundbeck A\/S, 2015. European Medicines Agency Summary of Product Characteristics: Brintellix."},{"key":"10.1016\/j.euroneuro.2016.03.007_bib15","doi-asserted-by":"crossref","first-page":"953","DOI":"10.4088\/JCP.11m07470","article-title":"A randomized, double-blind, placebo-controlled 8-week trial of the efficacy and tolerability of multiple doses of Lu AA21004 in adults with major depressive disorder","volume":"73","author":"Henigsberg","year":"2012","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2016.03.007_bib16","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1016\/j.euroneuro.2016.03.007_bib17","unstructured":"ICH, 2000. ICH Harmonised Tripartite Guideline Choice of Control Group and Related Issues in Clinical Trials. July 2000."},{"key":"10.1016\/j.euroneuro.2016.03.007_bib18","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1111\/jsm.12980","article-title":"Effect of vortioxetine vs. escitalopram on sexual functioning in adults with well-treated major depressive disorder experiencing SSRI-Induced sexual dysfunction","volume":"12","author":"Jacobsen","year":"2015","journal-title":"J. Sex. Med."},{"key":"10.1016\/j.euroneuro.2016.03.007_bib19","doi-asserted-by":"crossref","first-page":"575","DOI":"10.4088\/JCP.14m09335","article-title":"A randomized, double-blind, placebo-controlled study of the efficacy and safety of vortioxetine 10mg and 20mg in adults with major depressive disorder","volume":"76","author":"Jacobsen","year":"2015","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2016.03.007_bib20","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1017\/S1461145712000727","article-title":"A randomized, double-blind, placebo-controlled 6-wk trial of the efficacy and tolerability of 5mg vortioxetine in adults with major depressive disorder","volume":"16","author":"Jain","year":"2013","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2016.03.007_bib21","doi-asserted-by":"crossref","first-page":"10","DOI":"10.4088\/JCP.12m08001","article-title":"Comparison of longer-term safety and effectiveness of 4 atypical antipsychotics in patients over age 40: a trial using equipoise-stratified randomization","volume":"74","author":"Jin","year":"2013","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2016.03.007_bib22","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1097\/YIC.0b013e3283542457","article-title":"A randomized, double-blind, placebo-controlled, duloxetine-referenced, fixed-dose study comparing the efficacy and safety of Lu AA21004 in elderly patients with major depressive disorder","volume":"27","author":"Katona","year":"2012","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2016.03.007_bib23","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1111\/j.1755-5949.2010.00151.x","article-title":"Why has the antidepressant-placebo difference in antidepressant clinical trials diminished over the past three decades?","volume":"16","author":"Khan","year":"2010","journal-title":"CNS Neurosci. Ther."},{"key":"10.1016\/j.euroneuro.2016.03.007_bib24","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1097\/01.NMD.0000061144.16176.38","article-title":"Placebo response and antidepressant clinical trial outcome","volume":"191","author":"Khan","year":"2003","journal-title":"J. Nerv. Ment. Disord."},{"key":"10.1016\/j.euroneuro.2016.03.007_bib25","doi-asserted-by":"crossref","first-page":"464","DOI":"10.4088\/JCP.10m06191","article-title":"Exploratory analyses of efficacy data from major depressive disorder trials submitted to the US Food and Drug Administration in support of new drug applications","volume":"72","author":"Khin","year":"2011","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2016.03.007_bib26","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1097\/JCP.0b013e3181d20912","article-title":"Site versus centralized raters in a clinical depression trial: impact on patient selection and placebo response","volume":"30","author":"Kobak","year":"2010","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2016.03.007_bib27","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/1471-2288-5-14","article-title":"The strengths and limitations of meta-analyses based on aggregate data","volume":"5","author":"Lyman","year":"2005","journal-title":"BMC Med. Res. Methodol."},{"key":"10.1016\/j.euroneuro.2016.03.007_bib28","doi-asserted-by":"crossref","first-page":"583","DOI":"10.4088\/JCP.14m09337","article-title":"A randomized, double-blind, placebo-controlled study of the efficacy and safety of 2 doses of vortioxetine in adults with major depressive disorder","volume":"76","author":"Mahableshwarkar","year":"2015","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2016.03.007_bib29","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1185\/03007995.2012.761600","article-title":"A randomized, double-blind trial of 2.5mg and 5mg vortioxetine (Lu AA21004) versus placebo for 8 weeks in adults with major depressive disorder","volume":"29","author":"Mahableshwarkar","year":"2013","journal-title":"Curr. Med. Res. Opin."},{"key":"10.1016\/j.euroneuro.2016.03.007_bib30","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1007\/s00213-014-3839-0","article-title":"A randomized, double-blind, duloxetine-referenced study comparing efficacy and tolerability of 2 fixed doses of vortioxetine in the acute treatment of adults with MDD","volume":"232","author":"Mahableshwarkar","year":"2015","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.euroneuro.2016.03.007_bib31","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/1471-244X-4-26","article-title":"The efficacy of duloxetine: a comprehensive summary of results from MMRM and LOCF_ANCOVA in eight clinical trials","volume":"4","author":"Mallinckrodt","year":"2004","journal-title":"BMC Psychiatry"},{"key":"10.1016\/j.euroneuro.2016.03.007_bib32","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1016\/j.jpsychires.2011.03.001","article-title":"Recent developments in improving signal detection and reducing placebo response in psychiatric clinical trials","volume":"45","author":"Mallinckrodt","year":"2011","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.euroneuro.2016.03.007_bib33","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1111\/j.0006-341X.1999.01221.x","article-title":"On the equivalence of meta-analysis using literature and using individual patient data","volume":"55","author":"Mathew","year":"1999","journal-title":"Biometrics"},{"key":"10.1016\/j.euroneuro.2016.03.007_bib34","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1017\/S1461145714000546","article-title":"A randomized, double-blind, placebo-controlled study of vortioxetine on cognitive function in depressed adults","volume":"17","author":"McIntyre","year":"2014","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2016.03.007_bib35","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s13643-015-0001-y","article-title":"The safety and efficacy of vortioxetine for acute treatment of major depressive disorder: a systematic review and meta-analysis","volume":"4","author":"Meeker","year":"2015","journal-title":"Syst. Rev."},{"key":"10.1016\/j.euroneuro.2016.03.007_bib36","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/j.euroneuro.2008.06.003","article-title":"A regulatory Apologia--a review of placebo-controlled studies in regulatory submissions of new-generation antidepressants","volume":"18","author":"Melander","year":"2008","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2016.03.007_bib37","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1192\/bjp.134.4.382","article-title":"A new depression scale designed to be sensitive to change","volume":"134","author":"Montgomery","year":"1979","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2016.03.007_bib38","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1097\/YIC.0b013e32832a8eb2","article-title":"Is the significant superiority of escitalopram compared with other antidepressants clinically relevant?","volume":"24","author":"Montgomery","year":"2009","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2016.03.007_bib39","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1002\/hup.2424","volume":"29","author":"Montgomery","year":"2014","journal-title":"Hum. Psychopharmacol. Clin. Exp."},{"key":"10.1016\/j.euroneuro.2016.03.007_bib40","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1124\/jpet.111.189068","article-title":"Pharmacological effects of Lu AA21004: a novel multimodal compound for the treatment of major depressive disorder","volume":"340","author":"Mork","year":"2012","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.euroneuro.2016.03.007_bib41","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1097\/JCP.0b013e3180387820","article-title":"Is it easier to find what you are looking for if you think you know what it looks like?","volume":"27","author":"Mundt","year":"2007","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2016.03.007_bib42","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/S0022-3956(01)00011-5","article-title":"Baseline characteristics of major depressive disorder patients in clinical trials in Europe and United States: is there a transatlantic difference?","volume":"35","author":"Niklson","year":"2001","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.euroneuro.2016.03.007_bib43","unstructured":"Olkin, I., Sampson, A., 1996. Olkin I, Sampson A. Analysis of variance of individual patient data. Technical Report No. 315."},{"key":"10.1016\/j.euroneuro.2016.03.007_bib44","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1503\/jpn.140120","article-title":"Vortioxetine: a meta-analysis of 12 short-term, randomized, placebo-controlled clinical trials for the treatment of major depressive disorder","volume":"40","author":"Pae","year":"2015","journal-title":"J. Psychiatry Neurosci."},{"issue":"Suppl. E1","key":"10.1016\/j.euroneuro.2016.03.007_bib45","first-page":"e03","article-title":"The efficacy, tolerability, and safety of contemporary antidepressants","volume":"71","author":"Papakostas","year":"2010","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2016.03.007_bib46","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1176\/appi.ajp.2009.09060820","article-title":"Assuring that double-blind is blind","volume":"167","author":"Perlis","year":"2010","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2016.03.007_bib47","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1097\/01.pra.0000327313.81281.fd","article-title":"Flat dose\u2013response curves for efficacy: what do they mean to the clinician?","volume":"14","author":"Preskorn","year":"2008","journal-title":"J. Psychiatr. Pract."},{"key":"10.1016\/j.euroneuro.2016.03.007_bib48","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.pharmthera.2006.07.002","article-title":"Differentiating antidepressants of the future: efficacy and safety","volume":"113","author":"Rosenzweig-Lipson","year":"2007","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.euroneuro.2016.03.007_bib49","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1097\/JCP.0b013e31818c9ba3","article-title":"Use of remote centralized raters via live 2-way video in a multicenter clinical trial for schizophrenia","volume":"28","author":"Shen","year":"2008","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2016.03.007_bib50","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1080\/10543400802609797","article-title":"MMRM vs. LOCF: a comprehensive comparison based on simulation study and 25 NDA datasets","volume":"19","author":"Siddiqui","year":"2009","journal-title":"J. Biopharm. Stat."},{"key":"10.1016\/j.euroneuro.2016.03.007_bib51","unstructured":"Takeda, 2013. A multinational, randomized, double-blind, placebo-controlled, dose ranging study to assess the efficacy and safety of Lu AA21004 in patients with major depressive disorder. U.S. National Institutes of Health, In: ClinicalTrials.gov [Internet], p. NCT01255787."},{"key":"10.1016\/j.euroneuro.2016.03.007_bib52","unstructured":"Takeda Pharmaceuticals America Inc., 2014. Brintellix [package insert], Deerfield, IL."},{"key":"10.1016\/j.euroneuro.2016.03.007_bib53","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1176\/appi.ajp.163.1.28","article-title":"Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice","volume":"163","author":"Trivedi","year":"2006","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2016.03.007_bib54","series-title":"ClinicalTrials.gov Advanced Search","author":"US National Institutes of Health (NIH)","year":"2015"},{"key":"10.1016\/j.euroneuro.2016.03.007_bib55","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1017\/S146114571100040X","article-title":"Impact of geographical and cultural factors on clinical trials in acute mania: lessons from a ziprasidone and haloperidol placebo-controlled study","volume":"14","author":"Vieta","year":"2011","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2016.03.007_bib56","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1185\/03007995.2015.1014028","article-title":"Comparison of vortioxetine versus venlafaxine XR in adults in Asia with major depressive disorder: a randomised, double-blind study","volume":"31","author":"Wang","year":"2015","journal-title":"Curr. Med. Res. Opin."},{"key":"10.1016\/j.euroneuro.2016.03.007_bib57","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1007\/s11920-007-0061-3","article-title":"The STAR*D Project results: a comprehensive review of findings","volume":"9","author":"Warden","year":"2007","journal-title":"Curr. Psychiatry Rep."},{"key":"10.1016\/j.euroneuro.2016.03.007_bib500","first-page":"47","article-title":"In vitro and in vivo effects for the multimodal antidepressant vortioxetine (Lu AA21004) at human and rat targets","volume":"16","author":"Westrich","year":"2012","journal-title":"Int. J. Psychiatry Clin. Pract."},{"issue":"Suppl. 2","key":"10.1016\/j.euroneuro.2016.03.007_bib58","first-page":"Ii6-12","article-title":"Standardizing the Hamilton Depression Rating Scale: past, present, and future","volume":"251","author":"Williams","year":"2001","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."}],"container-title":["European Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X16300050?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X16300050?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,11,17]],"date-time":"2022-11-17T14:36:41Z","timestamp":1668695801000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924977X16300050"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6]]},"references-count":59,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2016,6]]}},"alternative-id":["S0924977X16300050"],"URL":"https:\/\/doi.org\/10.1016\/j.euroneuro.2016.03.007","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.726352410.793528766","asserted-by":"object"}]},"ISSN":["0924-977X"],"issn-type":[{"value":"0924-977X","type":"print"}],"subject":[],"published":{"date-parts":[[2016,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A meta-analysis of randomized, placebo-controlled trials of vortioxetine for the treatment of major depressive disorder in adults","name":"articletitle","label":"Article Title"},{"value":"European Neuropsychopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euroneuro.2016.03.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}